CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+17.27%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.31B
AUM Growth
+$1.31B
(-2.5%)
Cap. Flow
-$65.7M
Cap. Flow
% of AUM
-5.01%
Top 10 Holdings %
Top 10 Hldgs %
77.05%
Holding
39
New
3
Increased
8
Reduced
5
Closed
1
Top Buys
| 1 |
Illumina
ILMN
|
$24.2M |
| 2 |
GeneDx Holdings
WGS
|
$10.2M |
| 3 |
Relay Therapeutics
RLAY
|
$6.68M |
| 4 |
CTNM
Contineum Therapeutics
CTNM
|
$5.22M |
| 5 |
Century Therapeutics
IPSC
|
$5.06M |
Top Sells
| 1 |
Revolution Medicines
RVMD
|
$47M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$45.7M |
| 3 |
Structure Therapeutics
GPCR
|
$16.4M |
| 4 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
$10.8M |
| 5 |
AbCellera Biologics
ABCL
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioLife Solutions
BLFS
$1.2B
| $187M | 14.25% | 8,707,165 | – | – |
|
|
2
Revolution Medicines
RVMD
$7.1B
| $171M | 13.06% | 4,406,875 -1,210,724 | -22% | -$47M |
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $170M | 12.95% | 1,073,500 +4,500 | +0.4% | +$711K |
|
4
Standard BioTools
LAB
$481M
| $113M | 8.64% | 63,959,677 +2,052,072 | +3% | +$3.63M |
|
|
5
GeneDx Holdings
WGS
$3.72B
| $92.2M | 7.04% | 3,526,411 +390,000 | +12% | +$10.2M |
|
6
Avidity Biosciences
RNA
$5.99B
| $85.2M | 6.5% | 2,084,841 | – | – |
|
|
7
Relay Therapeutics
RLAY
$619M
| $55.1M | 4.21% | 8,448,574 +1,025,000 | +14% | +$6.68M |
|
|
8
Illumina
ILMN
$15.8B
| $50.1M | 3.83% | 480,000 +232,000 | +94% | +$24.2M |
|
9
Intellia Therapeutics
NTLA
$1.22B
| $44.8M | 3.42% | 2,000,000 +125,000 | +7% | +$2.8M |
|
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $41.3M | 3.15% | 170,000 -188,000 | -53% | -$45.7M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $35.2M | 2.69% | 326,378 | – | – |
|
12
Denali Therapeutics
DNLI
$2.23B
| $30.2M | 2.3% | 1,300,000 | – | – |
|
|
13
Structure Therapeutics
GPCR
$1.11B
| $27.5M | 2.1% | 700,000 -416,867 | -37% | -$16.4M |
|
14
Exact Sciences
EXAS
$8.98B
| $27.5M | 2.1% | 650,000 | – | – |
|
15
Tenaya Therapeutics
TNYA
$184M
| $20.9M | 1.59% | 6,732,971 | – | – |
|
16
Neurogene
NGNE
$264M
| $19.1M | 1.46% | 524,616 | – | – |
|
17
Veracyte
VCYT
$2.39B
| $18.6M | 1.42% | 857,904 | – | – |
|
18
4D Molecular Therapeutics
FDMT
$288M
| $16.8M | 1.28% | 800,000 | – | – |
|
19
Beam Therapeutics
BEAM
$1.66B
| $15.8M | 1.21% | 675,000 | – | – |
|
|
VERV
20
DELISTED
Verve Therapeutics
VERV
| $14.9M | 1.14% | 3,059,094 | – | – |
|
|
21
Century Therapeutics
IPSC
$42.5M
| $13.2M | 1.01% | 5,190,506 +1,984,126 | +62% | +$5.06M |
|
22
Pliant Therapeutics
PLRX
$101M
| $10.8M | 0.82% | 1,000,000 | – | – |
|
23
Tango Therapeutics
TNGX
$747M
| $10.2M | 0.78% | 1,188,349 | – | – |
|
|
TSVT
24
DELISTED
2seventy bio
TSVT
| $7.7M | 0.59% | 2,000,000 | – | – |
|
25
Codexis
CDXS
$246M
| $6.2M | 0.47% | 2,000,000 | – | – |
|